Catalyst
Slingshot members are tracking this event:
Vertex's Tezacaftor (VX-661) / ivacaftor in treating Cystic fibrosis - Two Copies of the F508del Mutation PDUFA date under priority review February 28, 2018
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| VRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Feb 12, 2018
Occurred Source:
http://investors.vrtx.com/releasedetail.cfm?ReleaseID=1057241
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Vx-661, Tezacaftor, Cystic Fibrosis, F508del Mutation
